Market Size of Egypt Diabetes Drugs Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 414.66 Million |
Market Size (2029) | USD 480.94 Million |
CAGR (2024 - 2029) | 3.01 % |
Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Egypt Diabetes Drugs Market Analysis
The Egypt Diabetes Drugs Market size is estimated at USD 414.66 million in 2024, and is expected to reach USD 480.94 million by 2029, growing at a CAGR of 3.01% during the forecast period (2024-2029).
The Egyptian diabetes drug market is driven by factors such as the rising prevalence of diabetes in Egypt and advancement in treatment options and government initiatives.
The increasing burden of diabetes in Egypt is significantly boosting the market for diabetes drugs. The prevalence of diabetes in Egypt has risen sharply due to factors such as urbanization, dietary changes, and sedentary lifestyles, which have created a substantial demand for effective diabetes management solutions. This rising incidence drives the need for a variety of diabetes medications, including oral hypoglycemics and insulin therapies, to manage and control blood sugar levels. For instance, according to the International Diabetes Federation (IDF) data published in 2022, the number of adults with diabetes in Egypt is projected to rise to 9.5 million by 2030 and 11.8 million by 2045.
In addition, as per a study article published in BMC Public Health in May 2023, Egypt has the 9th highest prevalence of diabetes worldwide, with around 18.4% of adults affected. This equates to over 11 million people with diagnosed type 2 diabetes. Diabetes is a major cause of premature mortality, morbidity, and loss of economic growth in Egypt. Sedentary lifestyles and unhealthy dietary habits, including increased consumption of processed foods, sugary drinks, and red meat, are contributing to the rise in diabetes prevalence in Egypt. Thus, the high burden of diabetes in Egypt is expected to increase demand for effective management, thereby contributing to market growth during the forecast period.
Further, government initiatives in Egypt are crucial in boosting the market for diabetes drugs. The Egyptian government has implemented various health policies and programs to tackle the rising prevalence of diabetes, including subsidized healthcare services, public awareness campaigns, and screening programs. These initiatives enhance early diagnosis and treatment, leading to increased demand for diabetes medications.
For instance, in March 2024, under the leadership of Dr. Ahmed El-Sobky, the Chairman of the Board and Supervisor General of the Universal Health Insurance and Haya Kareema projects at the Ministry of Health and Population, the Egypt Healthcare Authority unveiled the "Ramadan Health for the Whole Family" initiative. This initiative will be rolled out across provinces implementing the universal health insurance system. Dr. El-Sobky further elaborated that the initiative focuses on medical monitoring for three patient categories: individuals with diabetes, those with hypertension, and patients presenting both conditions. Thus, the government’s efforts to prioritize diabetes management in public health strategies and support the availability of innovative therapies, these initiatives are driving both demand and investment in the diabetes drug market.
Further, strategic activities by industry players in the country are expected to increase access to diabetes drugs, contributing to the market expansion during the forecast period. For instance, in December 2022, Egypt's Medical Union Pharmaceutical Company (MUP) unveiled a new high-capacity insulin production line, as announced by Khaled Abdel-Ghaffar, the Minister of Health and Population.
The high burden of diabetes, increasing government initiatives, and key strategic activities by market players in the country are all important factors. However, the high cost of treatment and limited infrastructure in the country are expected to restrain the market during the projected period.
Egypt Diabetes Drugs Industry Segmentation
Diabetes drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Egyptian diabetes drugs market is segmented into drugs.
The Egyptian diabetes drugs market is segmented into insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. By insulin, the market is segmented as basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and biosimilar insulins. By oral anti-diabetic drugs, the market is segmented as biguanides, alpha-glucosidase inhibitors, dopamine D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides. By non-insulin injectable drugs, the market is segmented as GLP-1 receptor agonists amylin analog. The market is segmented by combination drugs into insulin and oral combinations.
The report offers the value (USD) for the above segments.
Insulins | |
Basal or Long-acting Insulins | |
Bolus or Fast-acting Insulins | |
Traditional Human Insulins | |
Biosimilar Insulins |
Oral Anti-diabetic drugs | |
Biguanides | |
Alpha-glucosidase Inhibitors | |
Dopamine D2 Receptor Agonist | |
SGLT-2 Inhibitors | |
DPP-4 Inhibitors | |
Sulfonylureas | |
Meglitinides |
Non-insulin Injectable drugs | |
GLP-1 Receptor Agonists | |
Amylin Analogue |
Combination Drugs | |
Insulin Combinations | |
Oral Combinations |
Egypt Diabetes Drugs Market Size Summary
The Egypt Diabetes Drugs Market is poised for growth, driven by the increasing prevalence of diabetes in the country, which ranks ninth globally in terms of diabetes prevalence. The market is characterized by a significant demand for diabetic drugs, which are essential for managing blood glucose levels and preventing complications associated with the disease. The oral anti-diabetic drugs segment dominates the market due to their efficacy, safety, and cost-effectiveness, making them a preferred choice for treating type 2 diabetes. Initiatives like the Egyptian Government's '100 million Seha' program aim to raise awareness and improve diabetes management, further bolstering market prospects. The market is also witnessing advancements with the introduction of new drugs, such as Empagliflozin and Metformin Hydrochloride, which are designed to enhance glycemic control and reduce cardiovascular risks in diabetic patients.
Metformin, a key player in the market, is expected to maintain its dominance due to its role as a first-line treatment for hyperglycemia in type 2 diabetes and its anti-inflammatory properties. The market landscape is consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding significant shares. These companies are actively engaging in strategic mergers and acquisitions to expand their market presence and explore new revenue streams. Despite challenges such as limited healthcare access in rural areas and financial constraints affecting patient care, the government and healthcare providers are working towards improving access and affordability of diabetes treatments. The ongoing developments and strategic initiatives in the market indicate a positive growth trajectory for the Egypt Diabetes Drugs Market over the forecast period.
Egypt Diabetes Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Diabetes
-
1.2.2 Advancements in Treatment Options and Active Government Initiatives
-
-
1.3 Market Restraints
-
1.3.1 High Treatment Costs and Limited Healthcare Infrastructure
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulins
-
2.1.1 Basal or Long-acting Insulins
-
2.1.2 Bolus or Fast-acting Insulins
-
2.1.3 Traditional Human Insulins
-
2.1.4 Biosimilar Insulins
-
-
2.2 Oral Anti-diabetic drugs
-
2.2.1 Biguanides
-
2.2.2 Alpha-glucosidase Inhibitors
-
2.2.3 Dopamine D2 Receptor Agonist
-
2.2.4 SGLT-2 Inhibitors
-
2.2.5 DPP-4 Inhibitors
-
2.2.6 Sulfonylureas
-
2.2.7 Meglitinides
-
-
2.3 Non-insulin Injectable drugs
-
2.3.1 GLP-1 Receptor Agonists
-
2.3.2 Amylin Analogue
-
-
2.4 Combination Drugs
-
2.4.1 Insulin Combinations
-
2.4.2 Oral Combinations
-
-
Egypt Diabetes Drugs Market Size FAQs
How big is the Egypt Diabetes Drugs Market?
The Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million in 2024 and grow at a CAGR of 3.01% to reach USD 480.94 million by 2029.
What is the current Egypt Diabetes Drugs Market size?
In 2024, the Egypt Diabetes Drugs Market size is expected to reach USD 414.66 million.